Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus SYMBICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus SYMBICORT.
AZMACORT vs SYMBICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Symbicort is a combination product containing budesonide, a corticosteroid, and formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist (LABA). Budesonide reduces inflammation by inhibiting inflammatory mediators and suppressing airway hyperresponsiveness. Formoterol stimulates beta2-adrenergic receptors in bronchial smooth muscle, leading to bronchodilation via increased cyclic AMP. The combination provides anti-inflammatory and bronchodilatory effects.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
1-2 inhalations (80/4.5 mcg or 160/4.5 mcg) twice daily; maximum 2 inhalations twice daily of 160/4.5 mcg.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Budesonide: 2–3 hours (terminal); Formoterol: 10 hours (terminal). Clinical context: Twice-daily dosing maintains bronchodilation.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Budesonide: 60% renal (as metabolites), 40% fecal; Formoterol: 60% renal (as metabolites), 40% fecal.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/Long-Acting Beta Agonist